of a-2:a-1 activity. Because dexmedetomidine can provide sedation without significant respiratory depression or impairing reliable neurological examination, it is increasingly being used for various neurosurgical procedures as well as in the intensive care unit (ICU) 11 .
The purpose of this study was to evaluate the neurobiological changes of the injured brain under two different sedation strategies: propofol infusion discontinued prior to patient assessment, compared to a constant infusion of dexmedetomidine. In order to compare neurobiological responses, specific biochemical markers (lactate, pyruvate, lactate/ pyruvate ratio, glycerol, glucose and glutamate from microdialysis) were identified as substrates of cerebral metabolic activity and prognostic of patient outcomes 12 . We tested the hypothesis that in order to allow repeated awake neurological examinations, a strategy involving a sudden discontinuation of propofol is less favourable than allowing a constant infusion of dexmedetomidine in critically ill, braininjured patients.
METHODS
This prospective Phase IV, randomised, unblinded, single-crossover observational pilot study in patients with cerebral injury was approved by the Duke University Institutional Review Board (Pro00002077) and registered at clinicaltrials.gov (NCT00538616). Informed consent was obtained from patients' legal representatives before the initiation of any studyspecific procedures.
Patient population
Patients with a neurological or neurosurgical critical illness that required sedation and intracranial pressure (ICP) and parenchymal oximetry monitoring were screened and enrolled for this study between January 2008 and December 2009. Inclusion criteria included informed consent provided by the patient or their legal representative before initiation of any study related procedures; primary diagnosis of traumatic brain injury, intracerebral haemorrhage or subarachnoid haemorrhage; presence of mechanical ventilation; presence of invasive cerebral physiology monitoring; presence of pharmacological sedation; and ≥18 years old.
Exclusion criteria included bleeding diathesis; Glasgow Coma Score of <4 with fixed pupils; pregnancy; elevated ICP requiring deep sedation without interruption; pulmonary instability requiring deep sedation without interruption; treatment of alcohol withdrawal requiring the concurrent use of benzodiazepines; status epilepticus requiring pharmacologically induced coma; allergy or intolerance to either study medication; known history of current active pancreatitis; extubation planned within 12 hours from time of informed consent; participation in other therapeutic clinical research studies within 90 days of randomisation; and presence of neuromuscular blocking agents.
Study design
following informed consent, subjects were randomised in a 1:1 ratio to receive sedation with either propofol or dexmedetomidine as the primary sedating agent for the first six hours of the study. Both medications meet the requirement of being a standard of care medication in the NICU. In order to avoid the potential confounding effect of having different nurses adjusting drug doses and conducting the neurological evaluation for a single patient, the study period began at 0700 hours and lasted 12 hours, with the crossover commencing at 1300 hours and ending by 1900 hours. At the time of crossover, patients were transitioned from one group to the other group. In this manner, a patient could be randomised to propofol sedation from 0700 to 1300 hours and dexmedetomidine from 1300 to 1900 hours, or randomised to receive dexmedetomidine sedation from 0700 to 1300 hours and then crossover to propofol from 1300 to 1900 hours.
Sequence of procedures
The schedule of events (figure 1) summarises the study assessments by time point. The study consisted of pre-treatment (baseline evaluation), wash-in period A, treatment A, crossover, washin treatment B, treatment B and study termination. The pre-treatment or baseline period occurred prior to administration of study drug A and consisted of confirming eligibility, randomising the patient and collecting baseline assessments. Wash-in period A started from the time that study drug A was initiated (time=0) and lasted for two hours (time period=0 to second hours). Treatment Period A occurred from the end of the wash-in period A through the following four hours (time period=second to sixth hours). Crossover involved the discontinuation of study drug A and initiation of study drug B. Total dose of study drug A used up to this point was recorded. Wash-in period B started when study drug B was initiated and study drug A was discontinued (time period=sixth and seventh hours) and lasted for two hours. Treatment Period B occurred from the end of the wash-in period B through the following four hours (time period=8th to 12th hours). follow-up and study termination involved the discontinuation of the study drug B and initiation of sedation as ordered by the primary medical team. The cerebral physiology variables were recorded hourly for the next 12 hours. The study was completed at this point (time period=12th to 24th hours).
Sedation titration
An electrocerebral measure of sedation was ascertained using a Bispectral Index (BIS ® ) System (Model A2100, Covidien, Mansfield, MA, USA) score at baseline. Nurses adjusted sedation dosages of the study drug as determined by the patient's randomisation. Nurses caring for patients in both groups were instructed to adjust sedation according to the targeted Richmond Agitation Sedation Scale (RASS) first and then to the targeted BIS value ( Table  1 ). The initial RASS targeted was -2 and the initial BIS target was 60-70, although the primary medical team could adjust the sedation goal based on patient needs. The primary care team determined the drug dosing regimen to achieve the sedation goal for each subject without regard to study inclusion.
Cerebral physiology evaluation
Cerebral physiology was monitored using a triple lumen Licox ® Bolt system-IM3 (Integra Lifesciences, Plainsboro Township, NJ, USA) introduced through a single burr hole. The bolt was placed in a location that best represented the penumbral region of cerebral perfusion in the affected hemisphere (i.e. as close to the area of contusion, haemorrhage or infarction as possible). Concurrent ICP monitoring via an intraventricular catheter was performed by a member of the neurosurgery team. As is routine in the care of such patients, computed tomography imaging of the brain was used to assess catheter location. Two of the ports were used to introduce the brain temperature and oximetry (PbtO 2 ) catheters. The third port was used to introduce the microdialysis catheter.
Cerebral biochemistry measurements (microdialysis)
The microdialysis catheter was inserted to a depth of 30 mm via the Licox bolt system; this depth was calculated so that white matter would be monitored predominantly and so that the oximetry probe from the Licox catheter would be monitoring approximately the same region as the microdialysis catheter. The Licox and microdialysis catheters were inserted at least four hours before the start of the intervention study. The Licox bolt was inserted with the intention that both the microdialysis catheter and the oximetry probe were located adjacent to penumbral tissue, defined as a region 1 to 2 cm from the edge of the contused, haemorrhagic or ischaemic brain. The position of the probes was verified by computed tomography imaging after insertion. The microdialysis catheter was attached to the CMA106 perfusion pump (CMA, Stockholm, Sweden) and then perfused with artificial CSF solution for microdialysis (KCl 2.7mmol/l, NaCl 147 mmol/l, CaCl 1.2 mmol/l, MgCl 2 mmol/l) at a rate of 0.3 l/minute. Vials were changed every 30 minutes. The delay from the microdialysis membrane to the collecting vial (dead space) was 17 minutes and was accounted for in the study design. The initial 60-minute sample was used for analysis to allow for stabilisation of the probe. Microdialysis was not interrupted for transport or bedside testing.
Microdialysis samples were analysed for glucose, lactate, pyruvate, glutamate and glycerol using a CMA600 bedside microdialysis analyser. These 30-minute samples were run twice for each analyte and the mean value was used for analysis. Quality control measurements using normal saline and water blank samples, as well as standardised solutions across a range of concentrations (0.025 to 3.0 mmol/l) mimicking those of the human samples, were run weekly with an additional internal control sample for each subject. Acceptable values of coefficient of variation (3 to 5%) and accuracy were obtained to validate very low sample concentrations of selected analytes. Samples with extremely low values (<0.05 mmol/l) underwent repeat testing for confirmation.
Data acquisition
Baseline values for heart rate, blood pressure, ICP, cerebral perfusion pressure, PbtO 2 and BIS were recorded prior to the start of each wash-in period. To assess cerebral physiology before, during and after the neurological examination, we abstracted all recorded values from the electronic medical record and matched them to the nearest one-minute value for microdialysis data. Before the exam was defined as the one-hour period immediately preceding a scheduled neurologic exam (e.g. from 1100 to 1200 hours). During the exam was defined as the one-hour period that encompassed the neurological exam. At the top of the hour, nurses would stop the sedative infusion and perform a neurological examination when the patient was sufficiently awake to follow commands (e.g. sedative stopped at 1200 hours, exam performed at 1215 hours, sedative medications were then resumed and microdialysis samples obtained at 1300 hours). The next hour was a rest phase and defined the after the exam period of time (e.g. 1300 to 1400 hours). The average at the end of any given hour was used to define a single value when multiple measurements were obtained (e.g. when ICP was recorded four times during a single hour, the average ICP was entered as the value representing that period of time). Unweighted average values for the before, during and after the exam periods were explored using analysis of variance (SAS v 9.2; Cary, NC, USA).
Statistical analysis methods
Data were analysed using an intention-to-treat approach. Continuous data were described using medians and interquartile ranges or means and standard deviations, and categorical data using frequencies and proportions. We used Pearson's chisquare test for categorical variables and Wilcoxon signed-rank test for continuous variables to test for baseline differences between the two study groups. All statistical analyses were performed using SAS v 9.2 (SAS Institute, Cary, NC, USA). By convention, all P values are based on two-sided tests with <0.05 considered statistically significant and reported without adjustment for multiple comparisons.
RESULTS
In eight patients (four with traumatic brain injury, three subarachnoid haemorrhage and one intracerebral haemorrhage) with a mean baseline Glasgow Coma Score of 6.1 (range four to ten) and Acute Physiology and Chronic Health Evaluation II Scores of 13.5 (range one to 22), the mean dose of propofol used was 25.5 µg/kg/minute (or 1.5mg/kg/hour) while the mean dose of dexmedetomidine was 0.54 µg/kg/hour. All subjects were receiving propofol for a mean of 3.5 days (range 2 to 8.5 days) prior to study enrolment. Within 48 hours of study enrolment, six patients received midazolam, seven patients received fentanyl and four patients received hydromorphone. Sedation was discontinued for neurological examination and restarted at the pre-examination infusion rate in all cases for propofol and remained at the same infusion rate for dexmedetomidine for all subjects during the treatment periods. Mean RASS during treatment periods was not different between the two groups at -3.7 (range -3 to -4). We did not observe any statistically significant differences between the groups in any of the mean physiology measures collected ( Table 2 ). There were no differences in the measured outcomes when grouped by disease type. To assess the differences in cerebral physiological stress between the treatment groups, we analysed the physiology measures before, during and after the period of neurological examination. Although we demonstrated a difference in heart rate between groups after the neurological examination, we did not find any other differences between the groups or between the time points (Table 3) .
DISCUSSION
Data from this pilot study suggest that neither of the two different sedation strategies to allow repeated neurological examinations changes the neurobiology of the injured brain. Thus, until definitive studies are completed, clinicians should base their choice of sedative regimen on the profile of the sedative and the desired goals for a particular patient's care.
A variety of medications may be used to sedate brain-injured patients. Propofol is frequently used for sedation in the NICU as a routine component of medical care. It is a phospholipid-based parentallyadministered anaesthetic that is metabolised in the liver and excreted via the kidneys 13 . Propofol inhibits the N-methyl-D-aspartate subtype of glutamate receptors by channel-gating modulation and has agonistic activity at the gamma-aminobutyric acid receptors 8 . Propofol has a relatively short half-life, with sedative effects generally lasting from four to eight minutes when used in doses of 1.5 to 2.5 mg/kg/ hour, although the pharmacokinetic effect of propofol has been shown to be dependent on body weight, fat content and duration of infusion 9 . Its very short halflife and easy titratability for short-term infusions has made it a drug of choice among NICU practitioners across the United States.
In spite of these pharmacological advantages, prolonged use of propofol has been associated with adverse events, such as propofol infusion syndrome. The 'wearing off' time tends to increase with the duration of infusion 14 . Patients with a high body fat content have less predictable pharmacokinetics after prolonged use as a result of propofol being stored in fat, thus making the titration of this agent more challenging 15 . Because it is suspended in a fat solution, the infusion tubing may require changing every 24 hours in order to reduce potential infection 16 . High doses of propofol may be associated with an increased amylase and lipase, and on rare occasions the development of full-blown pancreatitis 17 . An agent without these idiosyncrasies, but with a short pharmacological half-life and easy titratability, would be preferable.
One possible advantage of using dexmedetomidine in the NICU is the ability to continue drug infusion while performing clinically reliable neurological examinations 19 . It has been commonly observed by physicians and nurses in the ICU that when patients on continuous propofol sedation are allowed to awak-en (by temporarily stopping the propofol infusion), they frequently experience neurologically adverse events such as agitation, increased ICP and decreased PbtO 2 20 . A drug that allowed a reproducible and reliable neurological examination without these adverse physiological effects on the injured brain would offer a significant advantage over currently utilised sedative regimens.
Increasingly, multimodal neurological monitoring is being used to meet the medical needs of severely brain-injured patients. Cerebral microdialysis is a cerebral monitoring technique that, although recently introduced in the United States, has been extensively utilised in Sweden and Germany to monitor cerebral biochemistry 21 . The central concept to cerebral microdialysis is that various substrates can be dialysed and subsequently analysed through the use of a small micropore catheter. These substrates enable sampling of brain neurochemistry and inferential assessment of brain metabolism. There is a robust and growing literature on cerebral microdialysis in patients with neurocritical care illnesses, such as subarachnoid haemorrhage and traumatic brain injury 22, 23 . Despite this, the exact relationship between microdialysis markers of metabolism and independent measures of metabolism has yet to be clearly defined for various disease states.
The purpose of this pilot study was to evaluate the neurobiological responses that arise as a result of a sudden cessation of propofol infusion compared to a constant continued infusion of dexmedetomidine. Specific biochemical markers that have been identified as the substrates of cerebral metabolic activity and are prognostically linked to patient outcomes 24, 25 were measured by established cerebral microdialysis techniques. Our working hypothesis was that a sedation strategy involving a sudden cessation of propofol infusion is less favourable than a constant infusion of dexmedetomidine. However, we were unable to demonstrate any differences in neurobiological changes between the two sedation techniques.
The variability suggests that we were not adequately powered to detect a difference between the two regimens. Since propofol was administered to all subjects prior to enrolment and the average duration of infusion was over three days prior to enrolment, intuitively, it is likely that effects of propofol may last beyond the initial wash-in period A. further, given the context sensitive half-lives of both propofol and dexmedetomidine, it is quite possible that study drug A may have influenced data generated in treatment B. However, despite an equal number of subjects being randomised to start with either drug, we did not find significant differences between the treatment arms. Regardless, this was a pilot trial to generate hypotheses regarding different approaches to sedation in this patient population. We believe our data suggest that either regimen may be acceptable from the standpoint of cerebral cellular physiology. Thus, the choice remains with the care team and should be made based on the sedation and patient care goals. It is important to reiterate that our data may not extrapolate to other ICU care settings, such as multisystem trauma and primary pulmonary disease, due to the primary outcome measure we used in this study (cerebral physiology). Also, we did not evaluate long-term outcome differences in our patient population. With emerging evidence suggesting that some forms of ICU sedation may result in cognitive impairment 26, 27 , follow-up study of the relationship of these two sedation techniques in the NICU patient population is important. furthermore, it is important to note that, for reasons determined by the clinical treatment team, patients were sedated to lower RASS and BIS scores than the initial targeted score. Thus it is possible that lack of differences seen between the groups was due, at least in part, to general oversedation resulting in a lack of change in physiological parameters regardless of sedative used. Additionally, it should be noted that we did not stratify our cohort based on the mechanism of brain injury. Though it is possible that the brain reacts differently to specific injuries 28, 29 , our intention was to evaluate the effects of sedation on cerebral physiology using the individual patient as their own control, which should also assist in controlling variations. Also, we were not able to control concurrent administration of other non-sedative medications such as antiepileptics, that might influence metabolism of propofol and/or dexmedetomidine and also some of the neurobiological changes. finally, it should be noted that, purely from a clinical perspective, changes in cerebral and cardiovascular physiology are not the only consideration in deciding which sedative agent is best for a brain-injured patient (e.g. dexmedetomdine has no anti-epileptic activities while propofol does). for all these reasons, a larger study population utilising longer drug infusion durations across a wider variety of brain injury mechanisms is required.
In summary, our pilot data demonstrate that dexmedetomedine appears to have comparable effects on cerebral and cardiovascular physiology to propofol in patients with brain injury at the doses used. Adequately powered clinical trials are needed to assess whether one agent is superior to another in achieving important patient-centred outcomes when used as a prolonged infusion for patients with brain injury.
